tbuckley/cabot-search huggingface dataset:
The treatment of locally advanced breast cancer.
Authors: G P Canellos
Journal: Journal of Clinical Oncology (1984)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1984.2.3.149 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 6699667 The treatment of locally advanced breast cancer. G P CanellosxG P CanellosSearch for articles by this author https://doi.org/10.1200/JCO.1984.2.3.149 First Page PDF © 1984 by American Society of Clinical Oncology
Abstract 250: Haploinsufficiency of Muscle-Enriched A-Type Lamin Interacting Protein (MLIP) Manifests as Enlarged Dilated Hearts
Authors: Patrick Burgon, Julia Lockwood, Glenn Wells, Alexandre Blais
Journal: Circulation Research (2012)

Approximately 116 unique mutations in the lamin A/C gene have been described to date that are associated with dilated cardiomyopathy. We recently reported the discovery of MLIP through its interaction with lamin A/C. MLIP is expressed ubiquitously and most abundantly in heart, skeletal and smooth muscle of amniotes (mammals, reptiles and birds) and has no paralogous homologue suggesting no functional redundancy. The MLIP gene encodes at least seven, alternatively spliced, LMNA-interacting factors that possess several structural motifs not found in any other protein. The MLIP isoforms pattern of expression differs between each of the tissues with heart being the most heterogeneous. Down-regulation of lamin A/C expression by shRNA results in the up-regulation and mis-localization of MLIP. In addition to interacting and co-localizing with lamin A/C we also demonstrated that MLIP localizes to micro-domains in the nucleus with promyelocytic leukemia protein (PML) in close proximity to chromatin. MLIP's biological function still remains elusive. Eight week old hemizygous MLIP null mice develop enlarged hearts with a significant increase in heart to body weights (MLIP+/+ 5.62mg/g vs MLIP+/- 10.73mg/g, p&lt;0.0001 n=7) with an overall 30% increase in the anterior-posterior ventricle length of MLIP hearts while maintaining a normal body weight (Figure). Echocardiographic analysis of MLIP+/- mice revealed that their hearts as having a significant (p3.93mm with a significant (p=0.011, n=12) reduction of left ventricular fractional shorting (LVFS) 31% when compare to littermate controls. Histological analysis of the hearts showed no overt phenotype other than an overall increase in the size of the MLIP+/- hearts. The cellular source for the increase in heart size and mass remains to be determined if it is the product of an increase in the number of cardiomyocytes due to aberrant hyperplasia or an increase in cardiomyocyte size through cellular hypertrophy. In conclusion, MLIP is a newly discovered lamin interacting protein that may serve as a transcriptional regulator that impact genes involved in heart development, growth and function and provides a new signaling paradigm.
Parent distress related to child health outcomes during hematopoietic stem cell transplant (HSCT).
Authors: Christina Kathleen Ullrich, Angie Mae Rodday, Susan Kenyon Parsons
Journal: Journal of Clinical Oncology (2014)

31 Background: HSCT offers possible cure yet remains intensive and high risk. Parent distress related to potential child outcomes during HSCT is unexplored. Methods: Parents of children undergoing HSCT (n=363) at 8 US transplant centers completed the Child Health Ratings Inventories (CHRIs) measuring parent and child general health and QOL at baseline (BL) through 12 mos post HSCT. Main outcomes: responses to 2 CHRIs items regarding parent worry about child "health worse" and "might die," rated on a 5-point Likert scale ranging from none to all of the time, and transformed to 1-100 (higher, more worry). Analyses focus on BL to D45 when parent worry decrease was pronounced. Clinical data were abstracted from charts. BL personal, clinical and HSCT course characteristics with p&lt;0.2 on univariate analysis were entered into multivariable models adjusting for transplant center, then eliminated by backward selection (p&lt;0.1). Results: Parents were 83% female, 77% White, median age 38.7 yr (IQR 33-44). Child median age was 9.6 yr (IQR 6-14). Most (72%) had cancer; 78% underwent allogeneic HSCT. By D45, 33% had systemic infection, 33% acute graft versus host disease (aGVHD) and 20% intermediate/poor Bearman toxicity score. Mean parent "might die" worry decreased from BL (41.9, SD 8.3) to D45 (26.6, SD 24.6) (p&lt;0.001). "Health worse" worry similarly decreased. Despite this, ongoing worry risk factors exist including younger child age, solid tumor and hematologic malignancy but not HSCT course characteristics (Table). Conclusions: Some parents remain at risk for unmitigated distress about child health, largely irrespective of the HSCT course. Enhanced supports such as palliative care consultation may be of benefit. [Table: see text]
Moving towards a uniform staging for human immunodeficiency virus-associated Kaposi's sarcoma.
Authors: P A Volberding
Journal: Journal of Clinical Oncology (1989)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1989.7.9.1184 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2769326 Moving towards a uniform staging for human immunodeficiency virus-associated Kaposi's sarcoma. P A VolberdingxP A VolberdingSearch for articles by this author https://doi.org/10.1200/JCO.1989.7.9.1184 PDF "Moving towards a uniform staging for human immunodeficiency virus-associated Kaposi's sarcoma.." Journal of Clinical Oncology, 7(9), pp. 1184–1185© 1989 by American Society of Clinical Oncology
The Meaning of a Combination Use of Bevacizumab in Reintroduction of Oxaliplatin for Metastatic Colorectal Cancer
Authors: Ken Nishimura, Norisuke Nakayama, Tomohisa Egawa, Takeshi Kenmochi, Ken Shimada, Yasutaka Takinishi, Koji Kobayashi, Tohru Sasaki, Sotaro Akatsuka, Atsushi Shirahata
Journal: Annals of Oncology (2014)
Preliminary effects of bright light on sleep in women with breast cancer
Authors: S. Ancoli-Israel, M. Rissling, V. Trofimenko, B. A. Parker
Journal: Journal of Clinical Oncology (2007)

9094 Background: Studies have shown that women with breast cancer undergoing chemotherapy report disturbed sleep. Studies have also suggested that these women have very little bright light exposure, yet it is known that bright light may improve sleep. We present preliminary data from an on-going study that addresses whether bright light improves sleep in women with breast cancer undergoing chemotherapy. Methods: 11 women (mean age=50.3 yrs, SD=8.4, range: 35–70 yrs) diagnosed with stage I-III breast cancer, scheduled to receive at least 4 cycles of adjuvant anthracycline-based chemotherapy participated. Sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI) and objective measures of sleep were assessed with 72-hours of actigraphy (Ambulatory Monitoring, Inc. and Respironics) at baseline (pre-chemotherapy) and during the last week of cycle 4 (C4). Participants were randomized into two treatment groups: bright white light (BWL; n=7) and dim red light (DRL; n=4). Both groups were instructed to self-administer light therapy for 30 minutes every morning throughout 4 cycles of chemotherapy. Results: In the BWL group, total sleep time (TST) increased by 41 min (SD=69), while wake time stayed approximately the same. In the DRL group TST decreased by 32 minutes (SD=30), while wake time increased by 27 minutes (SD=39). Subjectively, PSQI sleep latency subscale for BWL was reduced from 2.6 (SD=3.0, range=0–5) at baseline to 1.9 (SD=2.3, range=0–6) at C4, while for DRL, mean sleep latency increased from 2.7 (SD=2.5, range=0–5) at baseline to 3.0 (SD=3.0, range=0–6) at C4. PSQI total score for BWL decreased from 12.0 (SD=4.7, range=7–19) at baseline to 10.9 (SD=4.2, range=5–16) at C4 while for DRL it decreased from 8.3 (SD=3.1, range=5–11) at baseline to 7.7 (SD=5.1, range=2–12) at C4. Conclusions: Preliminary results suggest that bright white light may increase the number of hours of sleep in women undergoing chemotherapy, as well as decreasing sleep latency and improving sleep quality. As additional data are collected, we will be able to establish the significance of these effects. Supported by: CBCRP 11IB-0034, NCI CA112035, Litebook Company and the research service of the VASDHS. No significant financial relationships to disclose.
Study of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.
Authors: T. Kinoshita, T. Hojo, S. Asaga, J. Suzuki, K. Jimbo, N. Tamura
Journal: Journal of Clinical Oncology (2011)

104 Background: Despite the increasing use of both sentinel lymph node biopsy (SLNB) and preoperative chemotherapy (PST) in patients with operable breast cancer, there is still limited information on the feasibility and accuracy of SLNB following PST. In this study, the feasibility and accuracy of SLNB for breast cancer patients with clinically negative lymph nodes after PST were investigated. In addition, conditions that may affect SLN biopsy detection and false-negative rates with respect to clinical tumor response and clinical tumor/nodal status before PST were analyzed. Methods: Between 2003 and 2008, 200 patients with stage II and III breast cancer previously treated with PST were enrolled in this study. The eligible criteria for PST were (a) primary tumor &gt; 3cm or (b) positive axillary lymph node status on initial examination. FNA biopsy was performed for clinically or ultrasonographically suspicious axillary lymph nodes. The patients then underwent SLNB, which involved a combination of intradermal injection over the tumor of radiocolloid and subareolar injection of blue dye. This was followed by Level I/II axillary lymph node dissection (ALND). Results: The median patient age was 49 years, and the median primary tumor size was 4.9 cm. The overall SLN identification rate was 94.5% (189 of 200). In 178/189 patients (94%) the SLN accurately predicted the axillary status. Eleven patients had a false-negative SLN biopsies, yielding a false-negative rate of 12.9%. There were no significant differences in the SLN identification rate according to tumor classifications before PST, the clinical nodal status before PST, the clinical tumor response after PST, or pathological response of the tumor after PST, although the SLN identification rate tended to be lower in patients with a T4 primary tumor. Conclusions: Our data and some reports suggested that SLNB was feasible method for axillary staging in breast cancer patients who received PST even in patients who initially with lymph node positive disease. However, false-negative rate of SLNB in patients with clinical and pathological complete tumor response tended to be higher than other group.
Chemotherapy for breast cancer decreases plasma protein C and protein S.
Authors: J S Rogers, A J Murgo, J A Fontana, P C Raich
Journal: Journal of Clinical Oncology (1988)

An increased incidence of thromboembolic events has been described in women receiving chemotherapy for breast cancer. The etiology of this enhanced thrombotic state has not been defined. We performed serial coagulation studies in 15 women during 1 monthly cycle of cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy for breast cancer; seven adjuvant and eight metastatic. Plasma protein C levels were measured by anticoagulant, amidolytic, and antigenic techniques. Antigen levels of both total and free plasma protein S were quantitated by immunoelectrophoresis. Plasma levels of protein C, an important vitamin K-dependent inhibitor of blood coagulation and a profibrinolytic agent, and protein S, a cofactor for protein C, decreased 1 and 2 weeks after initiation of chemotherapy compared with pretreatment values. Plasma levels of factor VII and fibrinogen also decreased. The changes in protein C and protein S may contribute to the enhanced thrombotic tendency described in this setting. Possible mechanisms for the decreases in plasma protein C, protein S, factor VII, and fibrinogen are discussed.
Infectious Mononucleosis—Always a Primary Infection With Herpes-Type Virus?
Authors: David A. Stevens, Thomas W. Pry, Robert A. Manaker
Journal: JNCI Journal of the National Cancer Institute (1970)

Serum specimens drawn from 13 patients with infectious mononucleosis, at various times before and after the onset of clinical disease, were tested for antibodies to the herpes-type virus (Epstein-Barr virus) by the indirect immunofluorescence method. Pre-illness specimens from several patients reacted positively in low titer; in all these, there was a prominent elevation of titer in specimens taken after onset of disease. The remaining cases—a majority—were seronegative before illness and seropositive after the onset of disease. The implications of these observations in regard to the hypothesis that herpes-type virus causes infectious mononucleosis are discussed.
Increasing compliance with neuromuscular training to prevent ankle sprain in sport: does the ‘Strengthen your ankle’ mobile App make a difference? A randomised controlled trial
Authors: M Van Reijen, I Vriend, V Zuidema, W van Mechelen, E A Verhagen
Journal: British Journal of Sports Medicine (2016)

E-health has the potential to facilitate implementation of effective measures to prevent sports injuries.We evaluated whether an interactive mobile application containing a proven effective exercise programme to prevent recurrent ankle sprains resulted in higher compliance as compared with regular written exercise materials.220 athletes participated in this randomised controlled trial with a follow-up of 8 weeks; 110 athletes received a booklet explaining an 8-week neuromuscular training programme; 110 athletes participated in the same programme in an interactive mobile App (Strengthen your ankle). The primary outcome was compliance with the exercise programme. Secondary outcome measure was the incidence density of self-reported recurrent ankle sprains.The mean compliance to the exercise scheme was 73.3% (95% CI 67.7% to 78.1%) in the App group, compared with 76.7% (95% CI 71.9% to 82.3%) in the Booklet group. No significant difference in compliance was found between groups. The incidence densities of self-reported time-loss recurrences were not significantly different between both groups (HR 3.07; 95% CI 0.62 to 15.20).This study shows that the method of implementing the exercises by using an App or a Booklet does not lead to different compliance rates.The use of a mobile App or a Booklet lead to similar compliance and injury rates in the short term.The Netherlands National Trial Register NTR 4027. The NTR is part of the WHO Primary Registries.
Longitudinal Assessment of Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated on a Contemporary Chemotherapy Protocol
Authors: Lisa M. Jacola, Kevin R. Krull, Ching-Hon Pui, Deqing Pei, Cheng Cheng, Wilburn E. Reddick, Heather M. Conklin
Journal: Journal of Clinical Oncology (2016)

Purpose Survivors of childhood acute lymphoblastic leukemia (ALL) treated with CNS-directed chemotherapy are at risk for neurocognitive deficits. Prospective longitudinal studies are needed to clarify the neurodevelopmental trajectory in this vulnerable population. Methods Patients enrolled in the St. Jude Total Therapy Study XV, which omitted prophylactic cranial radiation therapy in all patients, completed comprehensive neuropsychological assessments at induction (n = 142), end of maintenance (n = 243), and 2 years after completion of therapy (n = 211). We report on longitudinal change in neurocognitive function and predictors of neurocognitive outcomes 2 years after completing therapy. Results Neurocognitive function was largely age appropriate 2 years after completing therapy; however, the overall group demonstrated significant attention deficits and a significantly greater frequency of learning problems as compared with national normative data (all P ≤ .005). Higher-intensity CNS-directed chemotherapy conferred elevated risk for difficulties in attention, processing speed, and academics (all P ≤ .01). The rate and direction of change in performance and caregiver-reported attention difficulties differed significantly by age at diagnosis and sex. End-of-therapy attention problems predicted lower academic scores 2 years later, with small to moderate effect sizes (│r│= 0.17 to 0.25, all P ≤ .05). Conclusion Two years after chemotherapy-only treatment, neurocognitive function is largely age appropriate. Nonetheless, survivors remain at elevated risk for attention problems that impact real-world functioning. Attention problems at the end of therapy predicted decreased academics 2 years later, suggesting an amplified functional impact of discrete neurocognitive difficulties. Age at diagnosis and patient sex may alter neurocognitive development in survivors of childhood ALL treated with chemotherapy-only protocols.
Development of a Web-based model to track patients’ self-reported symptoms related to anticancer treatment toxicities
Authors: G. Fasola, G. Aprile, V. Della Mea, M. Noselli, F. Puglisi
Journal: Journal of Clinical Oncology (2007)

17021 Background: Discrepancies outcropped when traditional modalities in collecting information regarding toxicities suffered by patients being exposed to anticancer treatments have been compared to direct self-reports. Owing to the availability of easily accessible informatics technologies, we hypothesized that a Web-site could be an accurate and reliable tool to directly record toxicity data. Methods: A database schema was designed, implemented with MySQL database management system and interfaced with the Web by using Java 2 Enterprise Edition on the Tomcat application container. A simplified, patient-adapted definition of type and NCI-CTCAE grade of the 15 commonest toxicities has been inserted into the database for reporting. The Web site has two areas, both accessible only with username and password, respectively devoted to patients and physicians. Through home Web access, each patient can report toxicities by choosing and grading any of them. Web site usability has been tested by 8 non-professional users with simulated scenarios. After a quick training, the users were asked to report the described toxicities. Time needed for reporting and reporting errors have been recorded. Results: The average time needed for entering a report has been 10 minutes. Users correctly reported the toxicities provided in the scenarios, but difficulties were noted in the correct identification of the week when entering reports for two or more weeks of therapy. Conclusions: In order to track patient-reported toxicities we developed a prototype Web-based model. Potential utilities of the system are being tested to demonstrate: 1) accuracy, allowing patients to easily report types and grades of the experienced toxicities; 2) flexibility, allowing patient-reporting either weekly or on demand; 3) capability to integrate and to assemble with an electronic patient record and a computerized physician order-entry. The latter capability will be provided by a patient portal with secure authentication and access being developed by the Regional Healthcare Authority. Comparative randomized analysis in 100 consecutive outpatients between clinical interviewing and Web-reported toxicity has been planned. No significant financial relationships to disclose.
Hypofractionated radiotherapy and hormonal therapy in elderly breast cancer patients
Authors: L. N. Minea, R. Anghel, I. Isacu, X. Bacinschi, A. Tarlea, T. Georgescu, T. Georgescu
Journal: Journal of Clinical Oncology (2009)

e20584 Background: Life expectancy increased in female population and we are facing higher incidence of breast cancer in patients over 80 years old. Considering age related comorbidities they are usually frail population which often can not receive chemotherapy or radical surgery. We evaluated once-a-week hypofractionated radiotherapy together with hormonal therapy for these patients in terms of local control, side effects and progression-free survival. Methods: Between January 2002 - December 2006 in the Oncological Institute of Bucharest Radiotherapy Department 59 patients with the age over 80 have been treated with once weekly hypofractionated radiotherapy associated with hormonal therapy. The clinical stage distribution was: stage I 9 patients, stage II 28 patients, stage III 22 patients. Radiation therapy was delivered once a week, dose=6.5 Gy, to a total dose of 32.5 Gy in 5 fractions for tumor site and lymph nodes. All patients received post irradiation hormonal therapy: Tamoxifen intended for 5 years. Results: 45 patients supporting the entire treatment (77%). 8 patients received less than 32.5 Gy (13%). 6 patients received less than 2 years hormonal therapy (10%). Radiotherapy led to: CR in 13 patients, PR in 31 patients, SD in 10 patients and PD in 5 patients. Toxicities after radiation therapy have been: grade 1–2 nausea in 6 patients, radiodermitis in 43 patients (grade 1–2 - 36 patients and grade 3–4 - 7 patients) and grade 1–2 leucopenia in 18 patients. Late toxicities of all grade occurred in 49.15% of patients: skin reaction - 19 patients, lung fibrosis - 8 patients (2 symptomatic and 6 asymptomatic) and cardiac failure - 2 patients. After one year 12 patients were free of disease and 38 patients were free of progression. 9 patients progressed; 4 of them died, 2 from their cancer. After two years 10 patients were free of disease and 35 free of progression. 14 patients dead and 4 death were cancer-related. Progression-free survival rate at 2 years was 76.27%. Conclusions: Definitive hypofractionated radiotherapy allows a good local control with acceptable toxicity and good progression free survival rate. This schedule associated with hormonal therapy is a good alternative to conventional multimodality treatment and to standard fractionation for patients over 80 years old. No significant financial relationships to disclose.
Doctor is struck off for racist remarks and poor clinical performance
Authors: Clare Dyer
Journal: BMJ (2015)

A doctor has been struck off the UK medical register after he repeatedly insulted Indian colleagues and then lied to employers about the resulting investigation and suspension by the General Medical Council (GMC).

Ragheb Nouman, a 52 year old Syrian, told the Medical Practitioners Tribunal Service’s fitness to practise hearing that he had acted under stress caused by the situation in his native land. But this was deemed insufficient to excuse a trail of offensive statements, some made directly to GMC investigators.

He also performed well below acceptable standards in the GMC’s clinical performance and knowledge assessments, which he was required …